Norroy Bioscience Starts Phase III Trial of 177Lu-NYM032
Wuxi, China, September 2, 2026 Norroy Bioscience has received regulatory clearance from China’s National Medical Products Administration (NMPA) to...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Wuxi, China, September 2, 2026 Norroy Bioscience has received regulatory clearance from China’s National Medical Products Administration (NMPA) to...
Daejeon, South Korea, September 2, 2026 Alteogen Inc. has entered into an option and license agreement with Novartis to...
MUMBAI, India & NAPLES, Fla., USA, March 31, 2026 Lupin Limited has received tentative approval from the U.S. Food...
